|
|
|
|
|
|
|
14.04.26 - 04:30
|
Research: M Stanley Raises PHARMARON TP to HKD31.5, Rating Overweight (AAStocks)
|
|
|
Morgan Stanley issued a research report updating the risk-reward profile of PHARMARON (03759.HK). The broker raised its target price from HKD31 to HKD31.5 and maintained an Overweight rating. In response to the groups 2025 results, the bank lifted its earnings forecasts for 2026 to 2030 by less than 1% to 3% to reflect higher r......
|
|
|
|
|
|
|
|
|
13.04.26 - 10:15
|
Research: M Stanley Trims 3SBIO TP to $34, Rating Overweight (AAStocks)
|
|
|
Morgan Stanley released a research report incorporating 3SBIO (01530.HK)'s 2025 results, and lowering its 2026-2028 revenue forecasts by 5%/ 7% / 6% each, due to reduced sales forecasts for 3SBIO's core commercialized product, TPIAO, and milestone payments, mainly affected by the depreciation of USD/ RMB. The broker also......
|
|
|
|
|
|
|
13.04.26 - 01:33
|
Nxera Pharma′s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia (GlobeNewswire EN)
|
|
|
Tokyo, Japan and Cambridge, UK, 13 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated and dosed the first patient(s) in a Phase 2 clinical study of NBI-1117570 (“NBI-'570”) in adults with schizophrenia. As a result, Nxera will receive milestone payments of US$22.5 million from Neurocrine pursuant to the agreement. The milestone payments will be recognised as revenue in Q1 FY2026. NBI-'570 is an investigational, orally administered, dual muscarinic M1/M4 receptor agonist discovered using Nxera's proprietary NxWave™ drug discovery platform....
|
|
|
|
|
|
|
10.04.26 - 09:30
|
China healthcare stocks outgain Hong Kong market as Middle East roils global investments (SCMP)
|
|
|
China's healthcare sector has been drawing offshore capital to Hong Kong-listed stocks as investors look for safe havens amid global volatility in commodities.
The Hang Seng Healthcare Index, tracking some of China's most innovative pharmaceutical companies including Akeso and Innovent Biologics, has surged about 13 per cent since March 23, outpacing the benchmark Hang Seng Index's about 6 per cent gain over the same period.
“Although the Middle East conflict has created a lot of uncertainty and......
|
|
|
10.04.26 - 08:48
|
Cereno Scientific to Participate at Nordic Health Summit Japan and ChinaBio Partnering Forum 2026 (Cision)
|
|
|
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will participate at Nordic Health Summit Japan, April 23–24, 2026 in Tokyo, Japan, and ChinaBio Partnering Forum, April 28–29, 2026 in Shanghai, China. The events provide strategic platforms to advance partnering discussions with potential pharmaceutical partners and strengthen Cereno Scientific's growing presence in key Asian markets aiming to maximize the value of its HDAC inhibitor...
|
|
|
10.04.26 - 02:03
|
Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases (PR Newswire)
|
|
|
SAN FRANCISCO and SUZHOU, China, April 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and......
|
|
|
|
|
09.04.26 - 15:36
|
Tender Offer for Yomeishu Seizo Completed (Nippon)
|
|
|
Tokyo, April 9 (Jiji Press)--Japan's Yomeishu Seizo Co. said Thursday that Reno, an investment firm linked to Japanese activist investor Yoshiaki Murakami, has successfully completed its tender offer for the medical liqueur maker. The move is part of a deal to sell part of Yomeishu Seizo's operations to Japanese herbal medicine maker Tsumura & Co. Related procedures are expected to be comple......
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
